Safety and efficacy of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRiTE)

被引：0
|
作者：
Kozloff, M.
Hainsworth, J.
Badrinath, S.
Cohn, A.
Flynn, P.
Steis, R.
Dong, W.
Suzuki, S.
Sarkar, S.
Sugrue, M.
Grothey, A.
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Genentech Inc, San Francisco, CA 94080 USA
[3] Atlanta Canc Care, Roswell, GA USA
[4] Abbott NW Hosp, Minneapolis, MN USA
[5] Rocky Mt Canc Ctr, Denver, CO USA
[6] Florida Oncol Associates, Jacksonville, FL USA
[7] Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA
[8] Univ Chicago, Chicago, IL 60637 USA
[9] Ingalls Hosp, Harvey, IL USA
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：24 / 24
页数：1
相关论文
共 50 条
  • [41] Safety and tolerability of first-line bevacizumab in metastatic colorectal cancer
    Akun, E.
    Okutur, K.
    Seber, S.
    Korkmaz, T.
    Aydin, K.
    Bozkurt, M.
    Namal, E.
    Hasbal, B.
    Tecimer, C.
    Demir, G.
    JOURNAL OF BUON, 2012, 17 (04): : 669 - 676
  • [42] Efficacy and safety of sintilimab plus bevacizumab and CAPOX as first-line treatment for patients with RAS-mutant, microsatellite stable, metastatic colorectal cancer
    Wang, Yanrong
    Jia, Ru
    Si, Haiyan
    Ma, Yue
    Fan, Mengjiao
    Zhang, Nan
    Liu, Fangfang
    Shi, Yue
    Jia, Yushan
    Zhang, Yaoyue
    Han, Quanli
    Wang, Zhikuan
    Dai, Guanghai
    BMC CANCER, 2025, 25 (01)
  • [43] A comparison of efficacy of first-line chemotherapy regimens for metastatic colorectal cancer (mCRC): FOLFIRI plus bevacizumab vs. XELIRI plus bevacizumab
    Ocvirk, J.
    Rebersek, M.
    Boc, M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 336 - 336
  • [44] CLINICAL OUTCOMES WITH FIRST-LINE BEVACIZUMAB AND CHEMOTHERAPY FOR PATIENTS WITH METASTATIC COLORECTAL CANCER AND A HISTORY OF DIABETES: RESULTS FROM THE ARIES OBSERVATIONAL COHORT STUDY
    Bendell, J.
    Cohn, A.
    Mun, Y.
    Fish, S.
    Sommer, N.
    Grothey, A.
    ANNALS OF ONCOLOGY, 2014, 25
  • [45] Serious bleeding events are uncommon in patients with metastatic colorectal cancer receiving bevacizumab as part of a first-line regimen. results from the brite observational cohort study
    Kozloff, M.
    Sugrue, M.
    Chiruvolu, P.
    Feng, S.
    Purdie, D.
    Grothey, A.
    Sargent, D.
    Berlin, J.
    Kabbinavar, F.
    Dong, W.
    Flynn, P.
    ANNALS OF ONCOLOGY, 2008, 19 : 25 - 25
  • [46] The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer Results from the Nordic ACT trial
    Hansen, Torben Frostrup
    Christensen, Rene dePont
    Andersen, Rikke Fredslund
    Spindler, Karen-Lise Garm
    Johnsson, Anders
    Jakobsen, Anders
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2012, 27 (06) : 715 - 720
  • [47] A COMPARISON OF XELIRI PLUS BEVACIZUMAB WITH FOLFIRI PLUS BEVACIZUMAB AS FIRST-LINE SETTING IN PATIENTS WITH METASTATIC COLORECTAL CANCER
    Ahmet, Bilici
    Uygun, Kazim
    Kaya, Serap
    Ustaalioglu, Bala Basak Oven
    Yildiz, Ramazan
    Temiz, Suleyman
    Seker, Mesut
    Aksu, Gorkem
    Cabuk, Devrim
    Gumus, Mahmut
    ANNALS OF ONCOLOGY, 2012, 23 : 98 - 99
  • [48] FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer
    Loupakis, F.
    Cremolini, C.
    Salvatore, L.
    Masi, G.
    Sensi, E.
    Schirripa, M.
    Michelucci, A.
    Pfanner, E.
    Brunetti, I.
    Lupi, C.
    Antoniotti, C.
    Bergamo, F.
    Lonardi, S.
    Zagonel, V.
    Simi, P.
    Fontanini, G.
    Falcone, A.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (01) : 57 - 63
  • [49] Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study
    Antonuzzo, Lorenzo
    Giommoni, Elisa
    Pastorelli, Davide
    Latiano, Tiziana
    Pavese, Ida
    Azzarello, Domenico
    Aieta, Michele
    Pastina, Ilaria
    Di Fabio, Francesca
    Bertolini, Alessandro
    Corsi, Domenico Cristiano
    Mogavero, Selene
    Angelini, Valentina
    Pazzagli, Mario
    Di Costanzo, Francesco
    WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (23) : 7281 - 7288
  • [50] FOLFIRI® and Bevacizumab in first-line treatment for colorectal cancer patients: Safety, efficacy and genetic polymorphisms
    Bécouarn Y.
    Cany L.
    Pulido M.
    Beyssac R.
    Texereau P.
    Le Morvan V.
    Béchade D.
    Brunet R.
    Aitouferoukh S.
    Lalet C.
    Mathoulin-Pélissier S.
    Fonck M.
    Robert J.
    BMC Research Notes, 7 (1)
12345